ANN ARBOR, Mich., – December 4, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has expanded research operations at its new Michigan facility with the appointment of a new lead molecular biologist.  In this role he will play a key part in developing the next generation of recombinant silk fibers and protein constructions as well as overseeing all aspects of our research laboratory.  Over the next 60 days the Company plans to hire additional research staff to support this role as the Company rapidly ramps up development of new and stronger transgenics and polymers. 

“After reviewing and screening numerous candidates for this crucial role, I am confident that we’ve found an ideal match,” said Jon Rice, COO.  “With excellent technical skills and a great cultural fit, he is already well on the way to making significant contributions to the team and our technology.  We expect great things from him over the coming quarter and I look forward to sharing those results with all of the Kraig Labs shareholders.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Happy Thanksgiving from Kraig Biocraft Laboratories. 

This week we witnessed the first silk moths emerging from cocoons that started from eggs in the new Michigan office.  This is just the first of many batches of many Silk moths we expect over the remainder of this month.  The new facility is currently housing Dragon Silk silkworms in all 5 instars’ (stages of growth) and is also rearing several other transgenic lines.  The Company expects to significantly expand throughput as we look to close out the fourth quarter on a high note. 

The Company has started hiring and training additional production staff and has hired a new a new molecular biologist, whom we’re very excited about.  He will be starting the week after thanksgiving.  

The build out of new Laboratory space in the Michigan office is well underway and equipment is already starting to come in.  Over the next several months we will be expanding our laboratory staff, equipment, space, and capabilities. 

Here are just a few of the images we took this week in the lab.

Below are Dragon Silk cocoons spun on the mounting mesh.  Within the next couple of weeks they will emerge and create the next generate of Dragon Silk silkworms

Dragon Silk Cocoons

Entering the second instar these silkworms below would fit on the tip of your finger, but are already 20 times larger than when newly hatched. 

2nd Instar Dragon Silk silkworms

Another batch is now in their third Instar, they are now half the length of your finger and the amount of food they consume is growing exponentially.  By the time they reach their 3^rd molt they will be more than 700 times their birth weight, roughly a week and a half ago.

3rd Instar Dragon Silk silkworms

Photos of emerged silk moths are always some of our favorites.  Here for Thanksgiving is a female Dragon Silk moth which emerged from cocoon this week and getting ready to take her place in growing our Dragon Silk colony.

Dragon Silk moth

2017 has been a great year for Kraig Labs and as we look forward to tomorrow’s holiday, we have much to be thankful for.  Opening our new research and production headquarter, expanding our production and research team, the follow on contract for the US Army, and opening our mulberry farm in Texas are just a few of the many significant milestones and accomplishments we’ve celebrated this year. 

From the entire Kraig Labs team, we wish you all a Happy Thanksgiving and a prosperous New Year

New fiber strains to complement the Company’s record setting Dragon Silk Technology

ANN ARBOR, Mich., – October 30, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)

(“Company”), the leading developer of spider silk based fibers, announced that it is now working to create a set of new custom designed transgenic silkworms under its contract with the US Army.  The Company is working with material performance objectives, defined by the customer, to develop entirely new genetically enhanced silkworm strains. 

These new silk polymers will be evaluated against defined performance requirements and the best performing materials will be scaled up to produce upwards of 100kgs of silk thread.  The Company expects the new strains to complement its record setting Dragon Silk fibers, but, with an eye on additional targeted applications, the fibers will be designed to generate even higher tensile strength.  As a result, these new enhanced fibers should provide outstanding performance in protective textile applications.

“This project is an excellent opportunity for us to demonstrate the incredible potential and power of engineered silk,” said COO Jon Rice.  “Tailoring the focus of our design efforts directly to a materials performance requirements is a perfect example of the amazing flexibility, and possibilities, of engineered proteins.  These new transgenics will be the beginning of our Enhanced Tactical Fiber (ETF) line of materials.  While a monumental moment for the Company, it is but one of many new and exciting opportunities for, spider silk, the Company, and our shareholders.”

To support this effort, the Company is hiring additional research and production staff and rapidly building out its in house lab capabilities at its Michigan based research and production center.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

New Facility to expand Kraig Labs’ Research and Production Programs

ANN ARBOR, Mich., – October 23, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced the Company successfully opened its new research and production headquarters, designed to significantly enhance domestic production of spider silk based fibers and centralize the Company’s research and development program for new polymers, in Michigan.

The Company relocated its production operations from Indiana into its new larger headquarters.  Hatching and rearing of silkworms at the new facility has already begun, with three separate strains.  Over the next sixty days, the Company plans to expand the new facility’s production.  

Kraig Labs is, concurrently, in the process of hiring personnel, in the field of molecular biology, to accelerate the work in engineering exciting new polymers.  Individuals with strong laboratory experience working in genetic engineering, and interested in taking a lead role in a fast paced, growing biotechnology company, are encouraged to apply, Click Here.

“It was only earlier this month we announced our plan for the new research and production center,” said Company founder and CEO, Kim K Thompson.  “Less than thirty days later the new facility is already up and running, which is a testament to our dedicated employees, who made the transition to our larger new headquarters as seamless and as efficiently as we had hoped.  We especially want to thank those who relocated to Michigan to make this next stage in our growth possible.  This facility will be dedicated to fulfilling our contract with the Army, moving our product line to commercialization, as well as developing exciting new fibers and materials for unique applications”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Company seen as nearing final clearance to begin hybridization in Vietnam

ANN ARBOR, Mich., -October 17, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that Company management has recently returned from a series of highly productive meetings with high level provincial and central government officials in Vietnam.  During these meetings the Company received the support and verbal approval to import the Company’s hybrid silkworms and begin selective breeding. This is the critical step in advancing the Company’s plans for commercial production in South East Asia.

During this trip, the Company’s management also met with its local architecture firm to review the master build plan for its proposed production site on 50 hectares.  Management also toured an existing facility which has been selected as the probable headquarters for its hybridization operations and early stage production. 

The Company is now working with officials from the Province as well as the Ministry to formalize the approvals granted during the meeting in Ha Noi. “To the best of our knowledge, clearance from one additional governmental unit is the only remaining regulatory hurdle to advancing the Company’s plans for selective breeding in Vietnam,” said COO Jon Rice.  The Company is now working with its consultants in Vietnam to expedite final clearance and to answer any additional questions or comments from the relevant Ministry.

“Obtaining this approval has been a lengthy process involving years of work in collecting data and conducting numerous meetings sharing that data with governmental agencies,” said CEO and Founder Kim Thompson. “The focus of those meetings has been answering their questions about our technology and how it can benefit the people and economy.  We believe that the most significant bureaucratic and regulatory hurdles are now behind us. We want to thank the governmental officials and other relevant parties who worked hard during this lengthy preparation and deliberative process.  We would also like to thank our loyal shareholders who have been navigating this lengthy regulatory process with us.  Without their support, none of our achievements would be possible.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Labs to expand its Research Team to support Domestic and International efforts

ANN ARBOR, Mich., – October 2, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced the Company is opening its new research and production headquarters in Michigan.  This facility will unite the Company’s ongoing recombinant spider silk production operations with its accelerating research into the creation of ever more powerful spider silk protein technologies. 

 Over the next 30 days, the Company will be relocating its current production operations, from Indiana into its new larger facility, and will transfer key production staff, to ensure continuity of operations.  This new facility offers better environmental control, roughly three times the production space, significantly reduces overhead costs, and, for the first time in the Company’s history, will allow the Company’s research and production teams to work side by side producing today’s spider silk based products, and creating tomorrow’s possibilities.

The Company created two new lead positions within its research group to support the new facility and growing research efforts.  Individuals with strong laboratory experience working in genetic engineered, and interested in taking a lead role in a fast paced, growing Biotechnology Company, are encouraged to apply, Click Here.

“Launching this new larger factory unifies our production and research teams’ efforts.  Having our teams working hand in hand will make us more agile and open up opportunities to move technologies more quickly from the drawing board to tested and validated designs,” said COO Jon Rice.    “In addition to streamlining developmental timelines and enhancing our ability to tailor fibers, we expect to reduce R&D costs, as we generate new spider silk technologies by fully integrating design, creation, testing, and scale up, under a single roof.  Our plan is to have this facility be the global central hub for spider silk technology and the center of our international operations.”

The Company’s domestic operations complement its ongoing work establishing international production centers.  Company management is currently considering three overseas locations for production.  Management is scheduled for meeting with senior central government officials in Hanoi, Vietnam in early October and is in ongoing discussions with another country silk producing country which has expressed interest in working with the Company to scale its spider silk technology.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Recent events position Kraig Labs with financial continuity and ability to focus on the Company’s Strategic Priorities

ANN ARBOR, Mich., -September 08, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company will not renew the equity line with Calm Seas Capital, which expired in June of 2017. 

The Company has maintained a financial relationship with Calm Seas Capital since before the creation of its first transgenic silkworm in 2010.  After careful consideration of its plan for commercialization and expansion, and after reviewing potential alternatives for financing that expansion, the Company’s management has determined it has outgrown the financial relationship. 

In addition to the recently extended U.S. Army contract, the Company implemented several strategic efficiency measures to reduce the Company’s fixed expenses.

“We value Calm Seas Capital’s contributions to many of our accomplishments, including the creation of new transgenics and recombinant fibers, however, given our projections for growth, this is the ideal time to transition for our business model’s next chapters,” said CEO and Founder, Kim Thompson.  “As the Company has grown, and, in light of our plans for future expansion and the Army’s recent exercise of its contract option with us for spider silk, it is timely for the Company to explore other avenues that are better aligned with our long term goals.  We’ve now grown to the point where we believe we have alternative financing options not previously available.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter    

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., -August 22, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)

(“Company”), the leading developer of spider silk based fibers, today announced that the Company delivered the first Dragon Silk fibers to a medical equipment firm for performance and application suitability testing.

The Company is dedicating its current Dragon Silk production to fulfilling its recently exercised U.S. Army contract, but in recognition of the abundant sample requests that the Company received and due to this healthcare firm’s extensive expertise in medical technology development and innovation, the Company decided to supply a small amount of fibers, to be tested for strength, elasticity, and other properties. 

“It seems like we learn about amazing new potential spider silk medical breakthroughs on a near weekly basis, so we believe that medical technologies will be a very important space for Kraig’s future,” said CEO and Founder Kim Thompson.  “As the promise of our fibers becomes increasingly evident, the tests will allow engineers and product designers to understand our fibers’ unique properties, work to define specific opportunities, and accelerate future fiber innovation.”

“It’s important to note that much of this research is for a commonplace application and it’s in very early stages, yet we hope that the tests help in guiding us in building the blueprint for future fiber designs,” stated Jon Rice, COO.  “Based upon the initial evaluation of the fibers we are already working to modify the properties of the finished threads for these applications.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com